Myeloma Milestones: Selinexor May Be Next Novel Agent While Established Drugs Expand Indications

Karyopharm's selinexor could be the next novel drug approved for multiple myeloma, which has seen a deluge of new treatment regimens. With room for improvement, the pipeline is full of milestones for approved and new therapies.

Open Book Of prostate multiple myeloma, Conceptual Image - Image
Several drugs are edging closer to approval. • Source: Shutterstock

Multiple myeloma has seen a deluge of new therapies and combination regimens in recent years aiming to extend progression-free survival and improve overall survival – and the flood is far from over.

Karyopharm Therapeutics Inc.'s selinexor may be the next novel agent to win US FDA approval, if the recent extension...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip